Toronto, Ontario – September 18, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has demonstrated 24 months long term stability of it lead anti-cancer PDC, TLD-1433. Stability studies are an essential component of pharmaceutical development, allowing evaluation of a drug’s stability under the influence of a variety of environmental factors such as: temperature, humidity and light. Data from these studies enable recommended storage conditions, retest intervals and shelf lives to be established. Demonstrating long term stability of a drug to be used in human clinical testing is essential to prove that the potency and/or efficacy of the drug is not affected during prolonged shelf life. TLD-1433, in the most recent testing report, demonstrated that its purity has … Read More

Toronto, Ontario – September 12, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has demonstrated increased efficacy with its latest, patented, licensed, anti-cancer drug, TLD-1633, when compared to its lead anti-cancer drug, TLD-1433. The latest PDC, known as TLD-1633, has recently been shown to be approximately 15% more effective than TLD-1433 in the destruction of a human Glioblastoma Multiforme (“GBM”) cell line (U87), a deadly form of brain cancer. In preclinical research, TLD-1633 has also demonstrated a lower dark toxicity, supporting an even higher safety profile than TLD-1433. TLD-1633 Photo Dynamic Therapy (“PDT”) when activated by green laser light (530 nm, 90 J/cm2) and dark toxicity (no laser light) compared to TLD-1433 in U87 GBM cells. Pavel … Read More

Toronto, Ontario – September 5, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its patented, lead anti-cancer drug, TLD-1433, has been proven effective in the destruction of a human cervical carcinoma cell line, ME180. The American Cancer Society’s estimates for cervical cancer in the United States for 2017 are: About 12,820 new cases of invasive cervical cancer will be diagnosed About 4,210 women will die from cervical cancer Cervical cancer was once one of the most common causes of cancer death for American women, but over the last 40 years, the cervical cancer death rate has gone down by more than 50%, due to the increased use of the Pap test. In research conducted by Pavel Kaspler, Ph.D., … Read More

Toronto, Ontario – August 29, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that for the six-month period ended June 30, 2017, total revenue increased to $1,016,734 from $893,138 for the same period in 2016, a 14% increase. In Canada, revenue increased 55% to $769,840 from $497,378. In the US, revenue decreased 33% to $211,453 from $316,756 and international revenue decreased 55% to $35,441 from $79,004. The increase in Canadian revenue in 2017 and the corresponding decrease in US and international revenue is attributable to the Company systematically building its sales and marketing teams in the Canadian market, the learning curves associated with training and developing a new sales force in the US and the ramp-up strategy of successfully … Read More

Toronto, Ontario – August 22, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its patented, lead anti-cancer drug, TLD-1433, and associated family of compounds, have been independently verified and validated in a peer-reviewed publication. A detailed computational investigation (“Study”) by Marta Alberto and coworkers entitled “Theoretical Exploration of Type I/Type II Dual Photoreactivity of Promising Ru(II) Dyads for PDT Approach”, appearing in the peer-reviewed American Chemical Society (“ACS”) journal Inorganic Chemistry, has independently verified and validated the unique photophysical properties of Theralase’s lead Photo Dynamic Compound (“PDC”), TLD-1433 and associated family of compounds. Click here to view The Study The Study details how Dr. Sherri McFarland (“McFarland”) has pioneered the use of specialized excited states for dual-mode Type … Read More

Toronto, Ontario – August 8, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer is pleased to announce that its lead compound, TLD-1433, combined with transferrin to form Rutherrin®, has been demonstrated to localize to and destroy various forms of lung cancer, when laser light activated, in an in-vitro and in an in-vivo animal model. Lung cancer is the leading cancer killer in both men and women. Out of all lung cancers, Non-Small Cell Lung Cancer (“NSCLC”) accounts for more than 85% of all lung cancers. In 2016, an estimated 20,800 Canadians died from lung cancer, representing 26% of all cancer deaths, while an estimated 158,080 Americans died, representing 27% of all cancer deaths. Current standard treatment for NSCLC is surgery followed … Read More

Toronto, Ontario – August 1, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the fourth patient was treated, utilizing the Therapeutic Dose (0.70 mg/cm2) on July 20, 2017 for Non-Muscle Invasive Bladder (“NMIBC”) cancer using its novel Photo Dynamic Therapy (“PDT”) technology. These patients come from a population that has failed standard of care and have remained drug resistant after the standard first line Bacillus Calmette Guérin (“BCG”) course of treatments. The Phase Ib NMIBC clinical study (“Study”) is entitled “A Phase Ib Trial of Intravesical Photodynamic Therapy in Patients with Non-Muscle Invasive Bladder Cancer at High Risk of Progression Who are Refractory to Therapy with Bacillus Calmette-Guérin (“BCG”) and Who are Medically Unfit for or Refuse a … Read More

Toronto, Ontario – July 25, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer is pleased to announce that at the Maximum Recommended Starting Dose (“MRSD”) (0.35 mg/cm2) of its lead compound, TLD-1433, at the ninety (90) day cystoscopy analysis, the Company has achieved the exploratory endpoint of efficacy in patients inflicted with Non-Muscle Invasive Bladder Cancer (“NMIBC”). These three patients come from a population that has failed standard of care and have remained drug resistant after the standard first line Bacillus Calmette Guérin (“BCG”) course of treatments. The exploratory efficacy endpoint is being reported at ninety (90) days, in the first 3 patients treated, in the first part of a Phase Ib clinical study (“Study“). The Study is entitled “A Phase … Read More

Toronto, Ontario – July 5, 2017   Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer is pleased to announce that release of two pre-recorded videos aired at the completion of the Company’s Annual and Special Meeting, held at the Company’s corporate office on June 30, 2017. The pre-recorded videos feature Dr. Michael Jewett, uro-oncologist of Princess Margaret Cancer Centre, University Health Network (“UHN”) and Dr. Girish Kulkarni, uro-oncologist, UHN. Youtube videos and links to both: Dr. Jewett Link: https://youtu.be/0awLP-R5gRA   Dr. Kulkarni Link: https://youtu.be/3P_Pvq1kzVc   Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase is delighted to be associated with both Dr. Jewett and Dr. Kulkarni and their combined expertise in the field of uro-oncology. Their experience and guidance is key … Read More

Toronto, Ontario – June 30, 2017   Further to its press releases dated November 1, 2016, May 1, 2017 and May 30, 2017, Theralase Technologies Inc. (“Theralase” or the “Corporation”) (TSXV:TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds to destroy cancer, wishes to provide clarification with respect to certain forward-looking statements included in a number of historical interviews conducted with management representatives from 2010 to 2016 and in certain corporate presentations prepared by the Corporation between 2013 and 2016. Such forward-looking statements included statements with respect to projected sales of up to $10 million per year for upcoming fiscal years, as well as certain other long term projections. Such statements may constitute forward-looking information within the meaning of National Instrument 51-102 – Continuous Disclosure and certain of those projections were subject to various underlying … Read More